Company intelligence / Profile preview

Hysun Biomedical

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Hysun Biomedical is a clinical-stage biotechnology company focused on developing innovative cell therapies for the treatment of cancer. The company leverages its proprietary STAR-T (Synthetic T cell Antigen Receptor) technology platform, which is designed to enhance the efficacy and safety of T-cell therapies against both liquid and solid tumors. Their lead programs include dual-targeting therapies for hematological malignancies and novel candidates for liver and lung cancers. Based in Shanghai, Hysun integrates research, development, and manufacturing capabilities to advance its pipeline through clinical trials.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-T cell therapyT cell receptor engineered T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Hysun Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hysun Biomedical.

Explore the full profile